Cargando…
The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma
Incidence and mortality of intrahepatic cholangiocarcinoma (iCCA) have been increasing continuously. Recent studies suggest that the combination of palliative chemotherapy (pCTX) and transarterial chemoembolization (TACE) improves overall survival (OS). This study aimed to evaluate the outcome of pa...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235389/ https://www.ncbi.nlm.nih.gov/pubmed/34205670 http://dx.doi.org/10.3390/jcm10122732 |
_version_ | 1783714306145124352 |
---|---|
author | Gairing, Simon Johannes Thol, Felix Müller, Lukas Hahn, Felix Thomaidis, Thomas Czauderna, Carolin Bartsch, Fabian Pitton, Michael Bernhard Marquardt, Jens Uwe Wörns, Marcus-Alexander Galle, Peter Robert Moehler, Markus Weinmann, Arndt Kloeckner, Roman Foerster, Friedrich |
author_facet | Gairing, Simon Johannes Thol, Felix Müller, Lukas Hahn, Felix Thomaidis, Thomas Czauderna, Carolin Bartsch, Fabian Pitton, Michael Bernhard Marquardt, Jens Uwe Wörns, Marcus-Alexander Galle, Peter Robert Moehler, Markus Weinmann, Arndt Kloeckner, Roman Foerster, Friedrich |
author_sort | Gairing, Simon Johannes |
collection | PubMed |
description | Incidence and mortality of intrahepatic cholangiocarcinoma (iCCA) have been increasing continuously. Recent studies suggest that the combination of palliative chemotherapy (pCTX) and transarterial chemoembolization (TACE) improves overall survival (OS). This study aimed to evaluate the outcome of patients treated with TACE and pCTX in unresectable iCCA at our tertiary care center. A group of 14 patients was treated with both pCTX and TACE. The non-randomized control group of 59 patients received pCTX alone. Patients received a median of two pCTX lines in both groups. Those treated with TACE underwent a median number of 3.5 sessions. Median OS from the time of unresectability was 26.2 months in the pCTX + TACE group versus 13.1 months in the pCTX group (p = 0.008). Controlling for albumin, bilirubin, ECOG (Eastern Cooperative Oncology Group) performance status, and UICC (Union for International Cancer Control) stage, the addition of TACE still conferred an OS benefit of 12.95 months (p = 0.014). A propensity score matching analysis yielded an OS benefit of 14 months from the time of unresectability for the pCTX + TACE group (p = 0.020). The addition of TACE to pCTX may provide an OS benefit for patients with unresectable iCCA. Thus, patients with liver-dominant iCCA undergoing standard-of-care pCTX should be considered for additional treatment with TACE. |
format | Online Article Text |
id | pubmed-8235389 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82353892021-06-27 The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma Gairing, Simon Johannes Thol, Felix Müller, Lukas Hahn, Felix Thomaidis, Thomas Czauderna, Carolin Bartsch, Fabian Pitton, Michael Bernhard Marquardt, Jens Uwe Wörns, Marcus-Alexander Galle, Peter Robert Moehler, Markus Weinmann, Arndt Kloeckner, Roman Foerster, Friedrich J Clin Med Article Incidence and mortality of intrahepatic cholangiocarcinoma (iCCA) have been increasing continuously. Recent studies suggest that the combination of palliative chemotherapy (pCTX) and transarterial chemoembolization (TACE) improves overall survival (OS). This study aimed to evaluate the outcome of patients treated with TACE and pCTX in unresectable iCCA at our tertiary care center. A group of 14 patients was treated with both pCTX and TACE. The non-randomized control group of 59 patients received pCTX alone. Patients received a median of two pCTX lines in both groups. Those treated with TACE underwent a median number of 3.5 sessions. Median OS from the time of unresectability was 26.2 months in the pCTX + TACE group versus 13.1 months in the pCTX group (p = 0.008). Controlling for albumin, bilirubin, ECOG (Eastern Cooperative Oncology Group) performance status, and UICC (Union for International Cancer Control) stage, the addition of TACE still conferred an OS benefit of 12.95 months (p = 0.014). A propensity score matching analysis yielded an OS benefit of 14 months from the time of unresectability for the pCTX + TACE group (p = 0.020). The addition of TACE to pCTX may provide an OS benefit for patients with unresectable iCCA. Thus, patients with liver-dominant iCCA undergoing standard-of-care pCTX should be considered for additional treatment with TACE. MDPI 2021-06-21 /pmc/articles/PMC8235389/ /pubmed/34205670 http://dx.doi.org/10.3390/jcm10122732 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gairing, Simon Johannes Thol, Felix Müller, Lukas Hahn, Felix Thomaidis, Thomas Czauderna, Carolin Bartsch, Fabian Pitton, Michael Bernhard Marquardt, Jens Uwe Wörns, Marcus-Alexander Galle, Peter Robert Moehler, Markus Weinmann, Arndt Kloeckner, Roman Foerster, Friedrich The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma |
title | The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma |
title_full | The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma |
title_fullStr | The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma |
title_full_unstemmed | The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma |
title_short | The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma |
title_sort | addition of transarterial chemoembolization to palliative chemotherapy extends survival in intrahepatic cholangiocarcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235389/ https://www.ncbi.nlm.nih.gov/pubmed/34205670 http://dx.doi.org/10.3390/jcm10122732 |
work_keys_str_mv | AT gairingsimonjohannes theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT tholfelix theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT mullerlukas theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT hahnfelix theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT thomaidisthomas theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT czaudernacarolin theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT bartschfabian theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT pittonmichaelbernhard theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT marquardtjensuwe theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT wornsmarcusalexander theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT gallepeterrobert theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT moehlermarkus theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT weinmannarndt theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT kloecknerroman theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT foersterfriedrich theadditionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT gairingsimonjohannes additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT tholfelix additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT mullerlukas additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT hahnfelix additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT thomaidisthomas additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT czaudernacarolin additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT bartschfabian additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT pittonmichaelbernhard additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT marquardtjensuwe additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT wornsmarcusalexander additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT gallepeterrobert additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT moehlermarkus additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT weinmannarndt additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT kloecknerroman additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma AT foersterfriedrich additionoftransarterialchemoembolizationtopalliativechemotherapyextendssurvivalinintrahepaticcholangiocarcinoma |